Fig. 8
From: Super enhancers targeting ZBTB16 in osteogenesis protect against osteoporosis
Targeting ZBTB16 protects against low bone mass and impaired bone repair in Brd4fl/fl Prx1-cre mice and OP models. a Immunoblot analysis of ZBTB16 protein expression in different organs of the Brd4fl/fl and Brd4fl/fl Prx1-cre mice. b Scatter plot showing the relative protein abundance of ZBTB16. c Diagram of rAAV9-ZBTB16 tail vein injection in mice with calvarial and femoral defects. d Immunoblot analysis showing the expression of neon green in different organs of the Brd4fl/fl Prx1-cre mice injected with rAAV9-ZBTB16 or the vector control. e Fluorescence image of the Brd4fl/fl Prx1-cre mice injected with rAAV9-ZBTB16. f Micro-CT analysis showing the calvarial and femoral defects of the Brd4fl/fl Prx1-cre mice treated with rAAV9-ZBTB16 or the rAAV9 vector control injection. g ARS and ALP staining of osteogenic differentiating MSCs extracted from the Brd4fl/fl Prx1-cre mice treated with rAAV9-ZBTB16 or rAAV9 vector control injection. Quantification of ARS and ALP is shown in the scatter plots. h Immunofluorescence showing the expression of BRD4 and ZBTB16 in femurs of the sham and OVX mice. i Workflow of rAAV9-ZBTB16 injection to treat the OVX mice. j Micro-CT analysis of the OVX mice treated with rAAV9-ZBTB16 or the rAAV9 vector control injection, and the trabecular bones were 3D reconstructed. Bone morphometric analysis was performed, and the parameters included BV/TV, Tb. Th, Tb. N, Tb. Sp and Ct. Th. The statistical data are represented as the means ± SEMs, n = 9 (n = 5 in j), *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001
